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Acquired elliptocytosis is a known but rarely described abnormality in the myelodysplastic syndromes (MDS). Here we report the
case of an elderly male who was admitted to the hospital with chest pain, dyspnea, and fatigue and was found to be anemic with
an elliptocytosis that had only recently been noted on peripheral smears of his blood. After bone marrow biopsy he was diagnosed
with MDS with ring sideroblasts and multilineage dysplasia and acquired elliptocytosis. Here we report a rare case of acquired
elliptocytosis cooccurring with MDS with ring sideroblasts and multilineage dysplasia.
1. Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal myeloid hemopathies that result in ineffective
development of one or more hematopoietic lineages. The
genetic alterations and other pathologic processes in the bone
marrow causing dysfunctional hematopoiesis lead to a wide
range of disease phenotypeswhich can range frommild single
lineage cytopenia to severe pancytopenia or transformation
to acute leukemia. Similarly diverse are the microscopic
characteristics of the dysplastic cells in the bone marrow and
peripheral blood.
In this report, we present the case of an elderly male
who was diagnosed with MDS after being admitted to our
hospital for symptomatic anemia. Review of his bonemarrow
biopsy showed twomorphological findings of particular note.
The first finding was ring sideroblasts, which are present
in about 25% of cases of MDS [1]. Ring sideroblasts are
erythroid precursor cells in which iron is unable to be
exported from the mitochondria due to one of a variety
of defects. This leads to an excess of iron within the mito-
chondria, which stains with Prussian blue, revealing the
so-called ring sideroblast. As with most findings in MDS,
ring sideroblasts are not specific to MDS but are found in
numerous congenital and acquired conditions encompassing
many genetic and acquired defects. Recently, mutations in a
gene coding for a portion of the U2 snRNP have been linked
to the development of ring sideroblasts inMDS. In one study,
SF3B1, located on chromosome 2 (http://genome.ucsc.edu)
was found to be mutated in 20% of all MDS cases and
65% of those with ring sideroblasts [2]. In another recent
study, 81% of MDS subtypes with ring sideroblasts had
SF3B1mutations [3]. It has been speculated that the mutated
proteinmay cause generalized downregulation of several core
pathways within the mitochondria, potentially accounting
for the higher frequency of ring sideroblasts observed in
patients with mutated SF3B1 [2]. The second finding in our
case was elliptocytosis, a finding which can be hereditary
or can be acquired. Hereditary elliptocytosis is caused by
mutations in in structural components of the erythrocyte
cell membrane. Mutations in genes coding for protein 4.1,
alpha spectrin, beta spectrin, band 3, and Glycophorin C
have all been implicated in hereditary elliptocytosis [4, 5].
Of note, other hereditary conditions, such as sickle cell
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anemia, thalassemias, and pyruvate kinase deficiency can
have elliptocytosis as a feature [4]. Acquired elliptocytosis is
sometimes seen in myeloid malignancies (including MDS)
as well as in iron deficiency anemia, megaloblastic anemias,
polycythemia, and myelofibrosis [5].
2. Case
A 70-year-old Caucasian male immigrant from Eastern
Europe with a 6-year history of anemia and an 8-year history
of thrombocytopenia was admitted to our hospital for chest
pain and dyspnea. At the time of his admission, his exam was
notable for mild scleral icterus and a palpable spleen 2 cm
below the costal margin.
He had undergone prior workup for his cytopenias
without a clear diagnosis. There was no family history of
anemia. He did not use alcohol. His medications included
amiodarone and ranolazine (medications associated with
bone marrow suppression), but no other medications known
to affect hematopoiesis. Records obtained documenting the
outpatient workup included studies showing normal vitamin
B12 and folate levels, decreased haptoglobin with a negative
Coombs test, and a bone marrow biopsy performed 2 years
earlier which showed a hypercellular marrow, moderate
erythroid hyperplasia, a deletion of chromosome 20q by
cytogenetics, 3-4% ring sideroblasts, and normal flow cytom-
etry studies. Based on these findings, there was concern
for a pre-MDS state, such as clonal cytopenia of undeter-
mined significance (CCUS). One month prior to admission,
a peripheral smear showed elliptocytosis. Physician’s notes
from the outpatient workup indicate that a peripheral smear
was reviewed 2 years earlier and there was no mention of
elliptocytosis or spherocytosis at that time.
At time of admission, the patient’s hemoglobin was
7.6 g/dL with an MCV of 91.1 𝜇m3, a platelet count of
28,000/mm3, white blood cell count of 5,200/mm3, and
absolute neutrophil count of 4,600/mm3. He had 6.7% retic-
ulocytes with an absolute reticulocyte count of 190,000/mm3.
His total bilirubin was elevated at 4.5mg/dL with direct
bilirubin of 2.4mg/dL. Transaminases were normal. LDH
was elevated at 349U/L, but haptoglobin levels were normal
and a direct Coombs test was negative. Methylmalonic acid
level was slightly elevated at 0.48𝜇mol/L (normal up to
0.40 𝜇mol/L). Thyroid studies and vitamin B12 levels were
normal. Folate was not checked. Ferritinwas 540 ng/mL, with
normal serum iron and transferrin levels. No paroxysmal
nocturnal hemoglobinuria clone was detected by peripheral
blood flow cytometry. Osmotic fragility was tested and found
to be normal. HIV screen was negative. Hematology was
consulted for diagnostic assistance. Review of the peripheral
smear showed marked elliptocytosis (Figure 1). A bone
marrow biopsy was performed which showed a hypercel-
lular marrow with erythroid hyperplasia, dyserythropoiesis
and dysmegakaryopoiesis, and adequate stainable iron with
>15% ring sideroblasts and 3% blasts (Figure 2). Cytogenetic
analysis showed 46,XY,del(20)(q11.2q13.3)/47,idem,+del(20)
[6].
Based on these findings, the patient was diagnosed
with MDS with ring sideroblasts and multilineage dysplasia
Figure 1: Peripheral blood smear (Wright-Giemsa stained, 100x):
peripheral smear showing anemia, with numerous elliptocytes and
thrombocytopenia.
(MDS-RS-MLD). His IPSS-R score was 5.5, stratifying him
to the high risk IPSS-R group, with an estimated median
overall survival of 1.6 years [7]. During his hospital stay he
received a total of 2 units of packed red blood cells and
1 unit of platelets, with resolution of his chest pain and
dyspnea. Prior to this time, he had not required transfu-
sion for his marrow disorder and had only received blood
product transfusions in the postoperative setting (distant
open heart surgery and others). He was discharged on
hospital day 6 with a follow-up appointment in hematol-
ogy clinic scheduled. He rescheduled the appointment for
unknown reasons and, unfortunately, passed away at home
approximately three weeks after discharge. No autopsy was
performed.
3. Discussion
Over the last 4 decades, understanding of the pathophysi-
ology of MDS has advanced considerably. As a result, there
have been revisions in classification and risk scoring of
MDS leading to improvements in the ability of clinicians
to offer a more accurate prognosis for affected patients.
Still, with the considerable heterogeneity and incomplete
understanding of MDS, additional investigations into the
mechanisms underlying the development of MDS will likely
yield new information and insight into disease progression
and refinements to MDS classification.
This case report describes a unique case of acquired ellip-
tocytosis presumably related to MDS, with a high percentage
of ring sideroblasts. MDS with ring sideroblasts is a relatively
common subtype of MDS, found in approximately 25% of all
MDS cases [1]. Acquired elliptocytosis in MDS, however, is
rare. Only 14 such cases are available in the literature to date
(Table 1). According to the 2016 WHO guidelines, a majority
of previously reported cases of acquired elliptocytosis in
MDS would be classified as either MDS with single lineage
dysplasia or multilineage dysplasia (10 of 14 cases) [8]. The
case reported in this paper is classified as MDS with ring
sideroblasts and multilineage dysplasia (MDS-RS-MLD) and
is now the 15th documented case of acquired elliptocytosis in
MDS. Of the 15 cases of MDS with an acquired elliptocytosis,
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Figure 2: (a) Bone marrow aspirate (Wright-Giemsa stain, 100x). High magnification of the bone marrow aspirate shows a marrow with
erythroid hyperplasia, megaloblastic maturation, and a dysplastic erythroid cell (arrow). (b) Bone marrow aspirate (Wright-Giemsa stained,
100x). Highmagnification of the bonemarrow aspirate shows a dysplastic megakaryocyte with separate lobes. (c) Bonemarrow aspirate (Iron
stain, 100x). The iron stained aspirate shows multiple ring sideroblasts (>15%) (arrows).
14 reported cytogenetics, and, of those 14 patients, 11 had
deletions of chromosome 20q.
While the causal factor(s) leading to acquisition of ellipto-
cytosis in cases of MDS have not been definitively identified,
several cases have noted decreased levels of human erythroid
protein 4.1 in association with del(20q) [9–11]. This protein
is a major cytoskeleton component in erythrocytes and
reductions in its levels are implicated in a small percentage
of cases of hereditary elliptocytosis [4, 5]. Interestingly, the
EPB41 gene, which codes for human erythroid protein 4.1
is found on chromosome 1 (http://genome.ucsc.edu) [9].
Since the common location of lost genetic material in most
of the cases of MDS with acquired elliptocytosis is on
chromosome 20, it has been hypothesized that the association
between del(20q) and reduced levels of human erythroid
protein 4.1 is a consequence of loss of factors affecting
transcription or splicing of the EPB41 gene’s mRNA [9]. Of
note, among the 14 known patients with MDS and acquired
elliptocytosis who have cytogenetic data available, only one
had a chromosome 1 abnormality and this patient also had
a deletion on chromosome 20 [12]. We can speculate that
there may be a role for cooperating mutations, possibly
involving splice factors such as the one coded for by SF3B1
and downregulation of EPB41 or another gene coding for
an erythrocyte membrane protein, leading to peripheral
elliptocytosis in MDS. Such a mechanism would provide an
explanation for the development of elliptocytosis inMDS and
at the same time link the seemingly unrelated observations of
decreased levels of human erythroid protein 4.1 and deletion
of chromosome 20q in MDS with acquired elliptocytosis
[9–11]. To evaluate this idea, future cases of MDS with
acquired elliptocytosis should be studied using techniques
such as next-generation sequencing based myeloid mutation
profiling, RNA-sequencing to evaluate mRNA expression,
and gene expression profiling.
A correlation between deletions on the long arm of
chromosome 20 and acquisition of elliptocytosis in MDS has
emerged since the first patient with acquired elliptocytosis in
what we now call MDS was reported by Hartz et al. in 1984
(then called preleukemic syndrome) and the first such case
where cytogenetic studies were performed by Rummens et
al. in 1986 [13, 14]. The focus of this report is on a rare and
interesting finding, but it should be noted that chromosome
20 deletions are not uncommon in MDS. Chromosome 20
deletions were found in 7% of MDS cases in one large
case series and are common enough to be included as a
variable in the IPSS-R for MDS [7, 15]. While del(20q) has
been shown to confer good cytogenetic risk, the impact of
acquired elliptocytosis on prognosis is unknown and may
benefit from further study [16].The observation that acquired
elliptocytosis seems to be related to del(20q) in MDS leads
one to question why acquired elliptocytosis is so rare, given
that 20q deletions are relatively common in MDS. To our
knowledge, this question has yet to be addressed. Future
research aimed at resolving this paradox may help to further
refine the categorization or risk stratification for patients
with MDS if a causative link between del(20q) and acquired
elliptocytosis can be established.
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